Cholera: A Disease That Can be Eradicated, Yet Remains a Persistent Threat
A devastating and preventable disease has taken hold in 32 countries, claiming over 6,800 lives so far this year. Cholera, an ancient foe that was last seen in Britain in 1866 and the United States in 1911, continues to spread rapidly, fueled by conflict, poverty, and inequality.
The World Health Organization (WHO) and its partners are working tirelessly to combat outbreaks through the Global Task Force on Cholera Control. A consortium of over 50 organizations, including WHO, has responded to these outbreaks with a partnership established in 1992, ensuring access to essential supplies, detection, prevention, and treatment services.
However, despite concerted efforts, cholera persists due to inadequate action from leaders. The disease is the definitive enemy of deprivation, thriving in communities afflicted by conflict, displacement, and climate-related disasters. Safe drinking water and sanitation are the only defenses against cholera, yet many countries lack these basic amenities.
Effective vaccines offer a lifeline against cholera, but vaccine development has been hindered due to limited market opportunities. The current manufacturer, EUBiologics from South Korea, produces vaccines at scale, but demand far exceeds supply. A global cholera vaccine stockpile, established in 2013, has dispensed over 255 million doses to 34 countries since its inception.
The ICG (International Coordinating Group on Vaccine Provision) has suspended the standard vaccination regimen in favor of a single dose to stretch supplies further. However, this is only a temporary solution as demand shows no signs of abating. New partnerships, such as Zambia and China's Jijia Medical Technology Company, aim to establish cholera vaccine-production facilities, but rigorous quality assurance and clinical trials are essential before locally manufactured doses can be approved.
The root cause of the cholera crisis lies not in a lack of scientific solutions, but rather in poverty, inequality, conflict, and displacement. Stopping this disease is fundamentally a political challenge. The WHO's Director-General Tedros Adhanom Ghebreyesus emphasizes that "cholera persists because poverty, inequality, conflict and displacement persist."
As the number of cholera cases continues to rise, it is clear that a collective effort is required to address this issue. Governments must prioritize investments in safe drinking water and sanitation, while vaccine manufacturers must increase production to meet growing demand. Ultimately, eradicating cholera will require sustained commitment from governments, international partners, and civil society.
A devastating and preventable disease has taken hold in 32 countries, claiming over 6,800 lives so far this year. Cholera, an ancient foe that was last seen in Britain in 1866 and the United States in 1911, continues to spread rapidly, fueled by conflict, poverty, and inequality.
The World Health Organization (WHO) and its partners are working tirelessly to combat outbreaks through the Global Task Force on Cholera Control. A consortium of over 50 organizations, including WHO, has responded to these outbreaks with a partnership established in 1992, ensuring access to essential supplies, detection, prevention, and treatment services.
However, despite concerted efforts, cholera persists due to inadequate action from leaders. The disease is the definitive enemy of deprivation, thriving in communities afflicted by conflict, displacement, and climate-related disasters. Safe drinking water and sanitation are the only defenses against cholera, yet many countries lack these basic amenities.
Effective vaccines offer a lifeline against cholera, but vaccine development has been hindered due to limited market opportunities. The current manufacturer, EUBiologics from South Korea, produces vaccines at scale, but demand far exceeds supply. A global cholera vaccine stockpile, established in 2013, has dispensed over 255 million doses to 34 countries since its inception.
The ICG (International Coordinating Group on Vaccine Provision) has suspended the standard vaccination regimen in favor of a single dose to stretch supplies further. However, this is only a temporary solution as demand shows no signs of abating. New partnerships, such as Zambia and China's Jijia Medical Technology Company, aim to establish cholera vaccine-production facilities, but rigorous quality assurance and clinical trials are essential before locally manufactured doses can be approved.
The root cause of the cholera crisis lies not in a lack of scientific solutions, but rather in poverty, inequality, conflict, and displacement. Stopping this disease is fundamentally a political challenge. The WHO's Director-General Tedros Adhanom Ghebreyesus emphasizes that "cholera persists because poverty, inequality, conflict and displacement persist."
As the number of cholera cases continues to rise, it is clear that a collective effort is required to address this issue. Governments must prioritize investments in safe drinking water and sanitation, while vaccine manufacturers must increase production to meet growing demand. Ultimately, eradicating cholera will require sustained commitment from governments, international partners, and civil society.